相关实验视频
Updated: Jul 26, 2026
12:21
Feeder-free Derivation of Melanocytes from Human Pluripotent Stem Cells
Published on: March 3, 2016
10.3K
精确药物重新定位:深度学习工具包,用于识别34个与超色素相关的基因并优化治疗选择
Shuwei Chen1, Junhao Zeng1, Mariam Saad2
1From the Department of Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Annals of plastic surgery
|June 19, 2024
概括
这项研究使用了计算方法来确定新的向性治疗方法. 先进的分析确定了关键的基因,并推了29种潜在的药物,为皮肤色素增多提供了新的治疗途径.
科学领域:
- 计算生物学是一种计算生物学.
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 超色素症涉及增加黑色素的产生,导致皮肤变黑.
- 目前的二次治疗方法,如化学皮肤和激光,存在风险,包括炎症后超色素化.
- 需要新的治疗策略来解决抗治疗性多色素问题.
研究的目的:
- 研究用于识别超色素的新型向治疗的计算方法.
- 使用综合生物信息学方法,精确定位与多颜色相关的关键基因.
- 通过药物基因相互作用分析,识别潜在的药物候选药物用于超色素治疗.
主要方法:
- 集成文本挖掘用于识别与超色素相关的基因.
- 使用GeneCodis,STRING和Cytoscape进行基因丰富和蛋白质-蛋白质相互作用分析.
- 雇佣Cortellis和DeepPurpose进行药物基因相互作用和药物标预测.
主要成果:
- 通过文本挖掘识别了34个与多颜色相关的基因.
- 通过综合生物信息学分析,突出发现了8个关键基因.
- 发现了35种针对相关基因的药物,其中29种由DeepPurpose推,包括M2PK1,KRAS和BRAF抑制剂.
结论:
- 先进的计算方法显示出确定新型超色素治疗方法的前景.
- 这项研究成功地确定了潜在的药物候选人,用于增色.
- 这种方法为开发针对性治疗皮肤超色素的治疗提供了新的方向.
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...